|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
RNA interference-mediated silencing of TRKB and TRKC, as well as treatment with the small-molecule TRK inhibitor lestaurtinib, reduced colony formation and proliferation in 3D primary cell cultures established from CYLD mutant tumours.
|
21552290 |
2011 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The sequential delivery vesicles showed the anticipated three-layered TEM structure and dual-convertible (surface charge- and particle size-reversible) features in the tumor environment (pH 6.5), which guaranteed the sequential release of siVEGF-CPPs and PTX in the tumor extracellular environment and tumor cells, respectively.
|
30144476 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Recent studies indicate that CYLD is a tumour-suppressor gene.
|
19076795 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In 1 patient only with 2 spiradenomas, both tumors harbored identical CYLD sequence alterations (c.1112C>A/S371X) in the CYLD gene and both showed loss of heterozygosity on chromosome 16q.
|
22588548 |
2013 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We conclude that somatic mutation of the CYLD1 gene outside the skin can have a role in the oncogenesis of tumors with cylindromatous features.
|
11756779 |
2002 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, knockdown of CYLD expression partially counteracted the tumor suppressive effects of miR-362-5p inhibitors.
|
25449782 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
This study aimed to assess subcellular CYLD expression in tumor tissues and its prognostic significance in HCC patients undergoing liver resection or liver transplantation.
|
25329885 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our recent work has shown that breast cancer cell adhesion to vascular endothelial cells activates endothelial MMP-2, promoting tumor cell transendothelial migration (TEM(E)).
|
20571065 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The tumor suppressor CYLD is a deubiquitinating enzyme that removes non-degradative ubiquitin linkages bound to a variety of signal transduction adaptors.
|
31067453 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The downregulation of miR21 and miR181b-1 and subsequent activation of PTEN/Akt and CYLD/IκB signaling axis leading to decreased NF-κB activity required to maintain the tumor-inhibiting effect of Rig-G.. Our findings contribute to a better understanding of the antitumor effect mechanism of Rig-G, as well as offer a novel strategy for lung cancer therapy.
|
27602766 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD in ubiquitin signaling and tumor pathogenesis.
|
16713556 |
2006 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.
|
26969893 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Together, our results argue that loss of CYLD instigates tumor growth in human cylindromatosis through a mechanism in which hyperubiquitination of polymerized Dvl drives enhancement of Wnt responses.
|
20227366 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We have found that the mechanisms through which CYLD regulates skin cancer progression include the control of tumor differentiation, angiogenesis and cell survival.
|
21900959 |
2011 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Further in line with these animal data, exogenous expression of CYLD(m) in A431, a human squamous cell carcinoma (SCC) cell line, markedly enhanced cell growth, migration, and subcutaneous tumor growth in an AP1-depdendent manner.
|
21478324 |
2011 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5<sup>+</sup> B cells through sustained canonical NF-κB signaling.
|
28566736 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The deubiquitinating enzyme CYLD is a negative regulator of NF-kappaB and known to function as a tumor suppressor.
|
20607853 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD(C/S) tumors are also characterized by their elevated proliferation rate and decreased apoptosis.
|
20838385 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We adopted three different methods: TEM, NTA and western blot analysis to characterize the cell-derived exosomes from NCI-H69 SCLC cell line and normal bronchial epithelial BEAS-2B cell line. we next explored the effects of these exosomes on HUVE cell proliferation and migration in vitro.To verify sFlt-1-loaded exosomes suppress the tumor growth in vivo,we established subcutaneous xenografts in nude mice using the NCI-H69 cell line.
|
31441580 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumor suppressor gene related to cylindroma and is negative regulator of NF-kappaB.
|
16627981 |
2006 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia.
|
25130432 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumour-suppressor gene that is mutated in a benign skin tumour syndrome called cylindromatosis.
|
19893491 |
2010 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Recurrent mutations were identified in tumor suppressor genes TP53 (n = 4), SMAD4 (n = 2), and CYLD (n = 2); and chromatin remodeling genes KDM6A (n = 3), SETD2 (n = 2), MLL3 (n = 2), and MLL2 (n = 2).
|
25299233 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Ten TSGs were up-regulated (FAM123B, RB1, TP53, RUNX1, MSH2, BRCA1, BRCA2, SOX9, NPM1, and RNF43); six TSGs were down-regulated (PAX5, IZKF1, GATA3, PRDM1, TET2, and CYLD); four were associated with MSI tumors (MLH1, PTCH1, and CEBPA down-regulated and MSH6 up-regulated); and two were associated with MSS tumors (PHF6 and ASXL1 up-regulated).
|
28675510 |
2017 |